CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 90 enrolled
Drug / intervention
Rivaroxaban +2 moredrug
Likely dose
Rivaroxaban 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03413618
NCT03413618Phase 4Completed
CompareCT.gov

The Efficacy of Rivaroxaban With Diosmin in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis

Pirogov Russian National Research Medical University·interventional·Posted Jan 29, 2018·Updated Feb 4, 2021

In Brief

A Phase 4 clinical trial evaluating Rivaroxaban, Diosmin, and 1 other intervention for Deep Vein Thrombosis and Postthrombotic Syndrome. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The randomized clinical study aimed to assess the efficacy and safety of standard anticoagulation with rivaroxaban in combination with diosmin compared to the isolated use of standard rivaroxaban for prolonged therapy of acute femoro-popliteal deep vein thrombosis reflected the speed of deep vein recanalization and incidence of post-thrombotic syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDeep Vein Thrombosis, Postthrombotic Syndrome
CountriesRussia
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJan 29, 2018
Enrollment StartDec 20, 2017
Primary CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.4 years ago

Interventions

Rivaroxabandrug

15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month

Diosmindrug

600 mg q.d. for 12 month

compression stockingsother

above knee stocking for 12 month